| Trial ID: | L2616 |
| Source ID: | NCT02420392
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Dapagliflozin
|
| Outcome Measures: |
Primary: Difference of incretin sensitivity of pancreatic beta cell measured by hyperglycemic clamp with GLP-1 and GIP infusion, Area under the curve of C-peptide level during GLP-1 infusion under hyperglycemic clamp, From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp | Secondary: First phase insulin/C-peptide response, From 0 to 10 minutes of hyperglycemic clamp|Second phase insulin/C-peptide response, From 10 to 60 minutes of hyperglycemic clamp|Area under the curve of insulin level during GLP-1 infusion under hyperglycemic clamp, From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp|Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp, From 120 minutes to 180 minutes during GIP infusion under hyperglycemic clamp|Difference of incretin sensitivity between diabetes patients and normal glucose tolerance subjects, Area under the curve of C-peptide level during GLP-1 infusion under hyperglycemic clamp, From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp|Difference of first phase insulin/C-peptide response between diabetes patients and normal glucose tolerance subjects, From 0 to 10 minutes of hyperglycemic clamp|Difference of second phase insulin/C-peptide response between diabetes patients and normal glucose tolerance subjects, From 10 to 60 minutes of hyperglycemic clamp|Difference of area under the curve of insulin level during GLP-1 infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects, From 60 minutes to 120 minutes during GLP-1 infusion under hyperglycemic clamp|Difference of Area under the curve of insulin/C-peptide level during GIP infusion under hyperglycemic clamp between diabetes patients and normal glucose tolerance subjects, From 120 minutes to 180 minutes during GIP infusion under hyperglycemic clamp
|
| Sponsor/Collaborators: |
Sponsor: Seoul National University Hospital | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
30
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2015-02
|
| Completion Date: |
2016-04
|
| Results First Posted: |
|
| Last Update Posted: |
2016-04-21
|
| Locations: |
Seoul National University Hospital, Seoul, 110-744, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT02420392
|
